# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ernest Shackleton (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EX001-SYN
- Date: 2026-06-23
- Fictional facility: St. Posthumous Health Center
- Fictional author: Cormac Ellingsworth-Daly, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Six-week review of angina on medical therapy; decision about coronary angiography. **S**

## History of present illness

Mr. Shackleton returns four weeks after his consultation. On metoprolol 100 mg his resting pulse is 60, but he still has chest tightness two or three times a week when he climbs the stairs carrying papers or walks fast into a cold wind, and he has used nitroglycerin four times. It never comes at rest. He has not smoked for five weeks. He is drinking within the limit he agreed. He sails in under three months, will be lifting and hauling at sea, and will be weeks from a hospital. He asked whether a stent would let him do that. He was uneasy about having a procedure that the backers might hear of, and said so; after talking it through he wants to go ahead. **S**

| Element | Detail |
|---|---|
| Angina | Two or three episodes a week despite metoprolol 100 mg |
| Nitroglycerin | Used four times |
| Tobacco | Not smoked for five weeks |
| Goal | To lead the expedition without angina limiting him |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Cardiovascular | Positive | Exertional angina unchanged in frequency; no rest pain or fainting |
| Respiratory | Negative | No cough or breathlessness apart from the angina |
| Gastrointestinal | Negative | Nausea on varenicline gone; no bleeding |
| Musculoskeletal | Negative | No muscle aches on the statin |

4 systems reviewed. **S**

## Current medications

- Aspirin 81 mg delayed-release tablet, one tablet by mouth daily **S**
- Atorvastatin 80 mg tablet, one tablet by mouth daily **S**
- Nitroglycerin 0.4 mg sublingual tablet, one tablet under the tongue for chest pain, repeat every 5 minutes up to 3 doses **S**
- Varenicline 1 mg tablet, one tablet by mouth twice a day after a one-week starter titration **S**
- Metoprolol succinate extended-release 100 mg tablet, one tablet by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 128/80 mmHg; pulse 60 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 85 kg; BMI 27.8 kg/m². All vital signs are synthetic.

Potassium: 4.3 mmol/L; Creatinine: 0.96 mg/dL; Hemoglobin: 15.6 g/dL; Platelets: 245 10*3/uL; eGFR: 98 mL/min/1.73 m². All results are synthetic.

## Change since baseline

- Potassium: 4.4 mmol/L at baseline, 4.3 mmol/L at this visit **S**
- Creatinine: 0.98 mg/dL at baseline, 0.96 mg/dL at this visit **S**
- Hemoglobin: 15.8 g/dL at baseline, 15.6 g/dL at this visit **S**
- eGFR: 96 mL/min/1.73 m² at baseline, 98 mL/min/1.73 m² at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 128/80, pulse 60, weight 85.0 kg |
| Cardiovascular | Regular rhythm; no murmur; both radial pulses normal, Allen test normal on the right |
| Respiratory | Clear to auscultation bilaterally |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Chronic coronary disease with stable angina despite medical therapy** (I25.118). Angina persists at class II despite a beta-blocker at a dose that holds his resting pulse at 60, with aspirin and a high-intensity statin. The options were explained: add a long-acting nitrate, amlodipine, or ranolazine; or coronary angiography and a stent to the proximal LAD lesion, which has a CT-FFR of 0.70. In stable coronary disease with normal heart function, a stent relieves angina better than medicines alone but does not lower the risk of heart attack or death. It means aspirin with clopidogrel for six months, which raises the risk of bleeding from injuries at sea. He chose angiography and a stent because he wants to work hard and haul loads on the expedition without angina, and he accepts the bleeding risk. Dr. Solberg-Adebayo agrees. Pre-procedure tests today: creatinine 0.96 mg/dL (eGFR 98), potassium 4.3 mmol/L, hemoglobin 15.6 g/dL, platelets 245 thousand per microliter. **S**
   - Coronary angiography by the right radial artery with a stent to the proximal LAD as a day case next week.
   - Clopidogrel 600 mg loading dose before the procedure, then 75 mg daily for six months with aspirin.
   - Continue metoprolol 100 mg, atorvastatin 80 mg, and nitroglycerin as needed.
2. **Nicotine dependence, cigarettes** (F17.210). Abstinent for five weeks. **S**
   - Continue varenicline.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure (target below 130/80 mmHg) | Every visit | Completed today | 128/80 mmHg, at target |
| Examination | Weight, BMI, and physical activity | Every visit | Completed today | 85.0 kg; walking more |
| Examination | Angina frequency and Canadian Cardiovascular Society class, nitroglycerin use | Every visit | Completed today | Class II despite optimized beta-blocker; nitroglycerin four times |
| Medication safety | Adherence review: aspirin (or dual antiplatelet therapy), high-intensity statin, beta-blocker for angina | Every visit | Completed today | All taken daily; resting pulse 60 on metoprolol 100 mg |
| Imaging | Invasive coronary angiography with a view to revascularization | For angina that persists despite guideline-directed medical therapy, or by shared decision | Ordered | Booked for next week after a shared decision |
| Laboratory | Creatinine, eGFR, potassium, hemoglobin, and platelets before angiography | Before contrast and antiplatelet loading | Completed today | Creatinine 0.96 mg/dL (eGFR 98), potassium 4.3 mmol/L, hemoglobin 15.6 g/dL, platelets 245 thousand per microliter |
| Imaging | Stress imaging, coronary CT angiography, echocardiography, or invasive angiography | Only for new or worsening symptoms or a change in function despite optimized therapy; no routine surveillance | Not indicated | No repeat noninvasive imaging; anatomy already defined |
| Laboratory | Lipid panel | 4 to 12 weeks after starting or changing lipid therapy, then every 3 to 12 months | Due | At ten weeks on atorvastatin, at the next visit |
| Self-management | Tobacco use and cessation support (varenicline with counseling) | Every visit | Completed today | Abstinent for five weeks |
| Survey | Alcohol use (AUDIT-C) and brief intervention | Each visit until within limits | Completed today | Within the agreed limit by his report; AUDIT-C at the next visit |
| Referral | Cardiac rehabilitation referral | At diagnosis of stable angina, and after PCI | Deferred | Still not made; to be made after the stent |

## Goal progress

- No cigarettes from the quit date, confirmed at each visit. In progress; target 2026-09-08. **S**
- LDL cholesterol below 55 mg/dL with at least a 50% reduction by four months. In progress; target 2026-09-08. **S**
- Blood pressure below 130/80 mmHg by six weeks. Outcome by 2026-06-23: 128/80 at six weeks. **S**
- Free of angina in daily activity, and a symptom-limited exercise test of at least 10 METs without ischemia before departure. In progress; target 2026-09-08. **S**
- Drinking within the low-risk limit, with an AUDIT-C below 4, by four months. In progress; target 2026-09-08. **S**
- At least 15 sessions of cardiac rehabilitation before departure. In progress; target 2026-09-08. **S**

## Guideline basis

- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (Virani SS, et al. Circulation 2023;148(9):e9-e119) (2023), American Heart Association and American College of Cardiology
- 2024 ESC Guidelines for the management of chronic coronary syndromes (Vrints C, et al. Eur Heart J 2024;45(36):3415-3537) (2024), European Society of Cardiology
- CMID: Clinical Monitoring Intelligence Database, ischemic heart disease and hyperlipidemia monographs (2026), Aether Forge
- Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021), U.S. Preventive Services Task Force
- Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions (2018), U.S. Preventive Services Task Force

## Follow-up

- Coronary angiography next week. Review three weeks after the procedure with a lipid panel. **S**
- Next scheduled visit 2026-07-21: ten-week review: three weeks after the stent, lipids, cardiac rehabilitation, smoking and alcohol. **S**
